New Treatment Methods for Hypertension/Chronic Renal Disease

Studies are underway that exam the safety and efficacy of newer antihypertensive agents, especially novel angiotensin II receptor antagonists on blood pressure and cardiovascular morbidity and mortality in patients with essential hypertension.

We are also participating in a large multicenter clinical trial comparing the effects of an angiotensin II receptor antagonist and a beta blocker on progression of renal disease in patients with type II diabetes and nephropathy.